Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) saw a large decrease in short interest in December. As of December 15th, there was short interest totalling 2,919,161 shares, a decrease of 35.2% from the November 30th total of 4,507,370 shares. Approximately 4.5% of the company’s shares are short sold. Based on an average daily volume of 1,263,200 shares, the short-interest ratio is currently 2.3 days.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Allianz Asset Management GmbH purchased a new stake in Arrowhead Pharmaceuticals during the 3rd quarter valued at $1,958,000. Dimensional Fund Advisors LP boosted its position in Arrowhead Pharmaceuticals by 252.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 44,358 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 31,765 shares during the period. Schwab Charles Investment Management Inc. boosted its position in Arrowhead Pharmaceuticals by 10.4% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 171,249 shares of the biotechnology company’s stock valued at $742,000 after buying an additional 16,103 shares during the period. ING Groep NV purchased a new stake in Arrowhead Pharmaceuticals during the 3rd quarter valued at $3,500,000. Finally, Virtu KCG Holdings LLC boosted its position in Arrowhead Pharmaceuticals by 115.6% during the 2nd quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 53,215 shares during the period. 20.05% of the stock is owned by institutional investors and hedge funds.

Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) opened at $3.68 on Friday. Arrowhead Pharmaceuticals has a 12 month low of $1.42 and a 12 month high of $4.54. The stock has a market cap of $275.37, a price-to-earnings ratio of -7.83 and a beta of 1.80. The company has a quick ratio of 3.63, a current ratio of 3.63 and a debt-to-equity ratio of 0.03.

A number of equities research analysts have recently issued reports on ARWR shares. ValuEngine cut shares of Arrowhead Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $2.00 price objective (up previously from $1.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, September 15th. Chardan Capital reaffirmed a “neutral” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, September 13th. William Blair raised shares of Arrowhead Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday, September 18th. Finally, Piper Jaffray Companies raised shares of Arrowhead Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $5.50 price objective for the company in a research note on Monday, November 27th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. Arrowhead Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $3.17.

WARNING: “Arrowhead Pharmaceuticals Inc (ARWR) Short Interest Down 35.2% in December” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://www.thecerbatgem.com/2017/12/30/arrowhead-pharmaceuticals-inc-arwr-short-interest-down-35-2-in-december.html.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.